Acrodermatitis chronica atrophicans overview

Revision as of 13:36, 16 June 2021 by Anahita (talk | contribs)
Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2] Raviteja Guddeti, M.B.B.S. [3]

Acrodermatitis chronica atrophicans Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Acrodermatitis chronica atrophicans from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acrodermatitis chronica atrophicans overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acrodermatitis chronica atrophicans overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acrodermatitis chronica atrophicans overview

CDC on Acrodermatitis chronica atrophicans overview

Acrodermatitis chronica atrophicans overview in the news

Blogs on Acrodermatitis chronica atrophicans overview

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Acrodermatitis chronica atrophicans overview

Overview

Acrodermatitis chronica atrophicans is a skin rash indicative of the third or late stage of European Lyme borreliosis. It is a dermatological condition that takes a chronically progressive course and finally leads to a widespread atrophy of the skin. Involvement of the peripheral nervous system is often observed, specifically polyneuropathy.

Historical Perspective

First record of acrodermatitis chronica atrophicans was made in 1883 in Breslau, Germany, where a physician named Alfred Buchwald first delineated it. Later in 1902 Herxheimer and Hartmann described it as a "tissue paper" like cutaneous atrophy and there were first physicians that came up with acrodermatitis chronica atrophicans's name. They described the biphasic manner of this disease by demonstrating both inflammatory and atrophic phases of it. In 1950s the possibility of human to human transmission was discussed.For the first time in 1984, borrelia was discovered as the responsible etiology of acrodermatitis chronica atrophicans.

Pathophysiology

Acrodermatitis chronica atrophicans is one of the tertiary presentations of European lyme borreliosis with Borrelia afzelii known as the most predominant responsible microorganism. Nevertheless other borrelia species such as borrelia garinii and borrelia burgdorferi (B. burgdorferi sensu lato) have been also detected in acrodermatitis chronica atrophicans patients. Transmission of this infection probably occur via ixodes tick (such as Ixodes ricinus), mosquito and horsefly bite. These vectors themselves get infected by feeding on an infected animal reservoir. Development of various symptoms in this disease is a result of chronic T cell mediated reaction of immune system against borrelia. This immune reaction leads to infiltration of CD3+ and CD4+ cells in the dermis. Borrelia is capable of attaching to the extracellular matrix proteins (such as glycosaminoglycan, fibronectin and decorin proteoglycan) which eventually leads to metalloproteases activation and extracellular matrix degradation. Pro-inflammatory cytokines, such as tumor necrosis factor alpha and interleukin-4, have been detected in skin biopsies. There is no known gene responsible in pathophysiology of acrodermatitis chronica atrophicans disease. Some conditions such as lymphocytic meningoradiculitis, lichen sclerosus et atrophicus, morphea and other tick borne diseases have been associated with acrodermatitis chronica atrophicans. Thinning of skin, visible veins, swelling and wrinkles are some of the features can be noticed on gross pathology. Light and electron microscopic study of the skin biopsy shows degeneration of the elastica and collagen fibers. Thinning of dermis and epidermis, pigmented stratum germinativum, dermal blood vessels dilation and perivascular plasma cell infiltration are some of the findings on microscopic pathology.

Causes

This progressive skin disorder is due to the effect of chronic infection with the spirochete borrelia afzelii, which is the predominant cause of acrodermatitis chronica atrophicans. However borrelia afzelii is not the exclusive etiologic agent of acrodermatitis chronica atrophicans and other microorganisms such as borrelia garinii and borrelia burgdorferi have also been detected.

Differentiating Acrodermatitis Chronica Atrophicans from Other Diseases

Acrodermatitis chronica atrophicans must be differentiated from chronic venous insufficiency, chronic arterial insufficiency, superficial thrombophlebitis, frostbite, morphea, erysipelas, acrocyanosis and granuloma annulare.

Epidemiology and Demographics

Acrodermatitis chronica atrophicans is a rare disease. The prevalence of acrodermatitis chronica atrophicans is estimated to include 10% of cases with lyme disease in Europe. The incidence of acrodermatitis chronica atrophicans increases with age and commonly affects individuals in range of 40 to 70 years old with a median of 64 years old. However there are few case reports on children who are diagnosed with acrodermatitis chronica atrophicans. Acrodermatitis chronica atrophicans affects women more than men. The majority of acrodermatitis chronica atrophicans cases are reported in northern, central and eastern Europe (most commonly in countries bordering the Baltic Sea). Lately few cases of acrodermatitis chronica atrophicans have been reported in the United States and Canada.

Risk Factors

Common risk factors in the development of acrodermatitis chronica atrophicans include tick exposure, female gender and residents of northern, central and eastern Europe.

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

References

Template:WH Template:WS